A Phase 2 interventional study of Relacorilant and Nab-paclitaxel in Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by Corcept Therapeutics. Completed at 24 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Ovarian Neoplasms.
Among the 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 7th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →2 of the 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ages 18–75 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 43 across the 15 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
Corcept Therapeutics has 4 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Albumin-Bound Paclitaxel in Ovarian Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR). The goals of this study are to evaluate the efficacy of relacorilant either administered daily (continuous) or on the day prior, the day of, and the day after chemotherapy (intermittent) in combination with nab-paclitaxel in the treatment of platinum-resistant ovarian, fallopian tube, or primary peritoneal cancers compared with nab-paclitaxel alone. The safety, pharmacokinetics (PK), and pharmacodynamic profile of relacorilant in combination with nab-paclitaxel will also be assessed.
Eligible patients will be randomized 1:1:1 to one of the following three treatment arms. Patient randomization will be stratified by treatment-free interval from most recent taxane (relapsed within 6 months vs >6 months) and presence of ascites (yes vs no).
Patients will remain on study treatment until reaching a protocol-defined event of disease progression (PD), experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for progression, subsequent therapies, and survival in the long-term follow-up phase. Patients in Arm C who experience unequivocal PD per RECIST v1.1 will be given the opportunity to receive relacorilant in combination with nab-paclitaxel after discussion with the Medical Monitor (Crossover patients).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Notes: For the calculation of the platinum-free interval, cancer progression must be defined by clear evidence of progression, such as radiographic progression per v1.1. Calculating the platinum-free interval on the basis of increased Cancer Antigen (CA-125) is not allowed.
Measurable or non- by RECIST v1.1:
Adequate organ and bone marrow function meeting the following criteria at the Screening Visit:
Negative pregnancy test for patients of . Patients of childbearing potential must use appropriate precautions to avoid pregnancy, defined as of non-childbearing potential (ie, or permanently sterilized) or using highly effective with low user-dependency, for at least 3 months after the last dose of relacorilant, or per the duration indicated in the product label for nab-paclitaxel, whichever is latest. A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy. Accepted methods of highly effective contraception with low-user-dependency are:
Exclusion Criteria:
Treatment with the following prior to randomization:
or current chronic/active infection with virus or virus, including:
Patient has a clinically significant uncontrolled condition(s) or which in the opinion of the Investigator may confound the results of the trial or interfere with the patient's participation, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive relacorilant 100 mg (titrated up to 150 mg after Cycle 1 or 2) once daily in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
Drug: Relacorilant · Drug: Nab-paclitaxel
Patients will receive relacorilant 150 mg on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel 80 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
Drug: Relacorilant · Drug: Nab-paclitaxel
Patients will receive nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle. Patients initially in Arm C who choose to cross over after disease progression will receive relacorilant 100 mg (titrated up to 150 mg) in combination with nab-paclitaxel 80 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle after cross over.
Drug: Relacorilant · Drug: Nab-paclitaxel
Relacorilant is supplied as capsules for oral dosing.
Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
Also known as: Abraxane
Progression-free Survival (PFS)
To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first.
Time frame: Baseline and up to 15 months
Objective Response Rate (ORR)
To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).
Time frame: Baseline and up to 15 months
Duration of Response (DOR)
To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first)
Time frame: From first documented response up to 12 months
Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG)
To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders.
Time frame: Baseline and up to 15 months
Best Overall Response (BOR)
To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death)
Time frame: Baseline and up to 15 months
PFS Rate at 6 and 12 Months
To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified.
Time frame: 6 and 12 months
PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first.
Time frame: Crossover Baseline (Day 50) up to Day 272
ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1
Time frame: Crossover Baseline (Day 50) up to Day 272
DOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first)
Time frame: From the time of objective response in the crossover period to the time of subsequent PD
BOR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD
To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period
Time frame: Crossover Baseline (Day 50) up to Day 272
Overall Survival (OS)
To assess the time from randomization to death by any cause.
Time frame: Up to 31 months
Overall Response According to Combined RECIST v1.1 + GCIG Criteria
To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample.
Time frame: Baseline and up to 15 months
The intent-to-treat (ITT) population included all randomized patients.
| Milestone | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Started | 58 | 60 | 60 |
| Entered crossover | 0 | 0 | 28 |
| Completed | 0 | 0 | 0 |
| Not completed | 58 | 60 | 60 |
| Withdrew: Death | 53 | 49 | 56 |
| Withdrew: Withdrawal by subject | 1 | 7 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Did not enter long-term follow-up | 3 | 3 | 2 |
To assess time from randomization until the date of first documented progressive disease (PD) by RECIST v1.1 (as determined by the Investigator at the local site), or death due to any cause, whichever occurs first.
| months | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Progression-free Survival (PFS) | 5.29 (3.84 to 5.55) | 5.55 (3.68 to 7.20) | 3.76 (3.52 to 5.36) |
To assess the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST v1.1 (confirmation not required).
| Participants | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Objective Response Rate (ORR) | 19 | 20 | 19 |
To assess the time from when response (CR or PR) was first documented to the first objectively documented PD or death (whichever occurs first)
| months | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Duration of Response (DOR) | 3.79 (2.33 to 5.55) | 5.55 (3.75 to 5.88) | 3.65 (2.89 to 5.09) |
To assess the overall CA-125 response per GCIG criteria. Response was defined as ≥50% reduction in CA-125 from a pre-treatment sample. Patients whose CA-125 levels fall within the reference range are classified as complete responders.
| Participants | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Cancer Antigen 125 (CA-125) Response According to Gynecological Cancer Intergroup Criteria (GCIG) | 32 | 34 | 28 |
To assess the best response (CR, PR, stable disease \[SD\], or PD) recorded from the date of randomization until PD/recurrence (or death)
| Participants | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Complete response | 4 | 1 | 2 |
| Partial response | 15 | 19 | 17 |
| Stable disease | 23 | 20 | 21 |
| Progressive disease | 9 | 14 | 12 |
| Not evaluable | 3 | 2 | 1 |
To assess the proportion of patients who have not progressed according to RECIST v1.1 criteria at 6 and 12 months. Values are Kaplan-Meier estimates of the patients progression-free at the time points specified.
| proportion of patients | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| 6 months | 0.26 (0.15 to 0.38) | 0.40 (0.28 to 0.53) | 0.25 (0.15 to 0.36) |
| 12 months | 0.08 (0.02 to 0.18) | 0.11 (0.04 to 0.23) | 0.04 (0.01 to 0.12) |
To assess the time from crossover Baseline (initial PD) until the earliest date of subsequent PD by RECIST v1.1, as determined by the Investigator at the local site, or death from any cause, whichever comes first.
| months | Crossover Patients |
|---|---|
| PFS in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | 2.10 (1.87 to 2.50) |
To assess the proportion of patients with measurable disease at the crossover Baseline who attain confirmed CR or PR by RECIST v1.1
| Participants | Crossover Patients |
|---|---|
| ORR in Patients Who Cross Over to Continuous Treatment at Time of Initial PD | 0 |
To assess the time from when the first objective response (CR or PR) in the crossover period to the first objectively documented subsequent PD, or death (whichever occurs first)
No measurements were reported for this outcome.
To assess the best overall response (CR, PR, SD, or PD) recorded in the crossover period
| Participants | Crossover Patients |
|---|---|
| Complete response | 0 |
| Partial response | 0 |
| Stable disease | 3 |
| Progressive disease | 18 |
| Not evaluable | 0 |
To assess the time from randomization to death by any cause.
| months | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Overall Survival (OS) | 11.30 (7.52 to 16.39) | 13.90 (11.07 to 18.43) | 12.19 (7.72 to 15.28) |
To assess the proportion of patients with measurable disease at Baseline who attain confirmed CR or PR by RECIST v1.1 and GCIG criteria. GCIG response was defined as ≥50% reduction in CA-125 from a pre-treatment sample.
| Participants | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Overall Response According to Combined RECIST v1.1 + GCIG Criteria | 34 | 36 | 33 |
Collected over Up to 39 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Continuous Relacorilant Dosing | 53/58 (91.4%) | 30/57 (52.6%) | 57/57 (100%) |
| Arm B: Intermittent Relacorilant Dosing | 49/60 (81.7%) | 15/60 (25%) | 59/60 (98.3%) |
| Arm C: Nab-paclitaxel Comparator | 56/60 (93.3%) | 19/60 (31.7%) | 60/60 (100%) |
| Event | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 5/57 | 2/60 | 2/60 |
| Abdominal painGastrointestinal disorders | 3/57 | 1/60 | 1/60 |
| Small intestinal obstructionGastrointestinal disorders | 3/57 | 1/60 | 1/60 |
| Pleural efffusionRespiratory, thoracic and mediastinal disorders | 3/57 | 1/60 | 1/60 |
| ConstipationGastrointestinal disorders | 2/57 | 0/60 | 0/60 |
| Large intestinal obstructionGastrointestinal disorders | 2/57 | 0/60 | 0/60 |
| VomitingGastrointestinal disorders | 2/57 | 0/60 | 0/60 |
| General physical health deteriorationGeneral disorders | 2/57 | 1/60 | 0/60 |
| PneumoniaInfections and infestations | 2/57 | 0/60 | 1/60 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/57 | 1/60 | 1/60 |
| Event | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator |
|---|---|---|---|
| NauseaGastrointestinal disorders | 41/57 | 30/60 | 27/60 |
| AnaemiaBlood and lymphatic system disorders | 39/57 | 29/60 | 34/60 |
| VomitingGastrointestinal disorders | 27/57 | 18/60 | 15/60 |
| Peripheral sensory neuropathyNervous system disorders | 26/57 | 18/60 | 14/60 |
| ConstipationGastrointestinal disorders | 25/57 | 19/60 | 17/60 |
| AstheniaGeneral disorders | 24/57 | 15/60 | 19/60 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/57 | 22/60 | 24/60 |
| DiarrhoeaGastrointestinal disorders | 22/57 | 16/60 | 15/60 |
| Abdominal painGastrointestinal disorders | 21/57 | 16/60 | 20/60 |
| NeutropeniaBlood and lymphatic system disorders | 20/57 | 11/60 | 20/60 |
The ITT population included all randomized patients.
| Age, Continuous(years) | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator | Total |
|---|---|---|---|---|
| Mean | 60.6 ± 8.8 | 60.3 ± 9.7 | 61.8 ± 8.8 | 60.9 ± 9.1 |
| Sex: Female, Male(Participants) | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator | Total |
|---|---|---|---|---|
| Female | 58 | 60 | 60 | 178 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 | 12 |
| Not Hispanic or Latino | 53 | 54 | 49 | 156 |
| Unknown or Not Reported | 2 | 3 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Arm A: Continuous Relacorilant Dosing | Arm B: Intermittent Relacorilant Dosing | Arm C: Nab-paclitaxel Comparator | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 57 | 52 | 50 | 159 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 5 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Mar 2021, 23 months.
Results were first posted in Apr 2025, 4 years 1 month after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 23 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relacorilant · Albumin-Bound Paclitaxel